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Mounting evidence suggests that inflammatory signaling pathways are central players 
in the pathogenesis of insulin resistance and type 2 diabetes. In this issue, Wellen et al. 
(2007) identify STAMP2 as a factor that integrates inflammatory and nutritional signals 
with metabolism.Cell 129, May 4, 2007 ©2007 Elsevier Inc. 451An important advance in recent 
metabolic disease research has 
been the elucidation of links 
between inflammatory signaling 
pathways and glucose/lipid metab-
olism. An early catalyst for research 
in this area was the discovery by 
Hotamisligil and Spiegelman that 
the cytokine TNFα is produced by 
adipose tissue in obese animals and 
contributes to the development of 
insulin resistance (Hotamisligil et al., 
1993). A number of other cytokines 
and signaling molecules—includ-
ing IL-6, JNK, IKKβ, and SOCS 
proteins—have subsequently been 
linked to insulin resistance induced 
by obesity (Shoelson et al., 2006; 
Wellen and Hotamisligil, 2005). A 
common theme to emerge from 
many of these studies is that inflam-
matory effector pathways such as 
those activated by JNK and NF-κB 
directly antagonize the actions of 
insulin in metabolic tissues such 
as liver, fat, and skeletal muscle 
(Hotamisligil, 2006). Recent stud-
ies have also highlighted a poten-
tially important role for adipose tis-
sue macrophages in the production 
of inflammatory mediators and the 
development of insulin resistance in 
obese mice (Weisberg et al., 2003; 
Xu et al., 2003). Although the exact 
triggers for macrophage accumula-
tion in obese adipose tissue are not 
clear yet, the chemokine MCP-1 and 
its receptor CCR2 have been shown 
to be involved in this process (Neels 
and Olefsky, 2006). Flier and col-
leagues have recently shown that 
Toll-like receptor 4 (TLR4)—which mediates activation of the NF-κB 
pathway in response to bacterial 
lipopolysaccharide—is also acti-
vated by nutritional fatty acids. This 
observation suggests a provoca-
tive mechanism whereby free fatty 
acids, levels of which are often 
increased in obesity and diabetes, 
may actually cause inflammation in 
metabolic tissues (Shi et al., 2006).
Wellen et al. (2007) now identify 
the transmembrane protein STAMP2 
as a factor that links inflamma-
tory and diet-derived signals to 
adipocyte function and systemic 
metabolism. The authors used 
transcriptional profiling to search 
for genes that were downregulated 
in adipose tissue of obese (ob/ob) 
mice both in the absence of TNFα 
and upon treatment with the PPARγ 
agonist thiazolidinedione (TZD). 
STAMP2 was selected for detailed 
analysis based on its preferential 
expression in adipose tissue. Stud-
ies in the 3T3-L1 adipocyte cell line 
revealed that expression of STAMP2 
was induced not only by TNFα but 
also by nutritional stimuli such as 
oleic acid or serum. In vivo, STAMP2 
expression was induced by feeding, 
and this physiologic response was 
lost in ob/ob mice or in mice ren-
dered obese through a high-fat diet. 
The pattern of STAMP2 expression 
and regulation raised the possibility 
that this protein might coordinate 
inflammatory responses with meta-
bolic pathways in adipose tissue.
To define the physiological role 
of STAMP2, Wellen et al. performed 
loss-of-function studies in vitro and in vivo. In 3T3-L1 adipocytes, 
knockdown of STAMP2 expres-
sion with small interfering (si)RNAs 
resulted in augmented IL-6 produc-
tion in response to either TNFα or 
high glucose stimulation. Loss of 
STAMP2 was also associated with 
decreased responses to insulin, 
including reduced phosphorylation 
of insulin signaling molecules such 
as the insulin receptor and Akt, 
and reduced glucose transport. In 
line with these in vitro results, loss 
of STAMP2 expression in vivo was 
sufficient to cause inflammation in 
adipose tissue. STAMP2 knockout 
mice exhibited increased expres-
sion of inflammatory mediators such 
as TNFα, IL-6, MCP-1, SOCS-3, and 
haptoglobin as well as increased 
numbers of macrophages in their 
adipose tissue under basal con-
ditions on a normal diet. Further-
more, consistent with the increased 
cytokine production observed in 
cultured adipocytes, induction 
of IL-6 and SOCS-3 expression 
in response to glucose and lipid 
administration was augmented in 
STAMP2-deficient mice.
The hypothesis that inflammation 
in metabolic tissues contributes to 
the development of insulin resist-
ance is the focus of intense research. 
With their analysis of the STAMP2 
knockout mice, Wellen et al. pro-
vide strong support for this notion. 
In short, STAMP2 deficiency mim-
ics many aspects of metabolic syn-
drome in humans. At the systemic 
level, STAMP2 deficiency results in 
impaired insulin sensitivity and dysli-
figure 1. STAMP2 at the crossroads of Inflammation and Metabolism
STAMP2 integrates nutrient and inflammatory signals with metabolic pathways in adipocytes. 
Nutritional stimuli (oleic acid or feeding) and the inflammatory cytokine TNFα induce expres-
sion of the transmembrane protein STAMP2 in adipocytes (Wellen et al., 2007). Expression of 
STAMP2 is required for normal insulin signaling, including tyrosine phosphorylation of both the 
insulin receptor (IR) and Akt kinase, translocation of the glucose transporter GLUT4 to the plasma 
membrane, and glucose uptake. Loss of STAMP2 expression also leads to enhanced production 
of inflammatory cytokines such as IL-6 and MCP-1 by adipose tissue.pidemia (abnormal blood lipid levels). 
Mice lacking STAMP2 had markedly 
higher plasma glucose, insulin, trig-
lyceride, and cholesterol levels and 
developed hepatic steatosis (fatty 
liver). They also showed impaired 
glucose metabolism in key meta-
bolic tissues (liver, skeletal muscle, 
and adipose). At the molecular level, 
these physiologic defects were asso-
ciated with impaired insulin receptor 
signaling in liver and adipose tissue. 
The ability of STAMP2—which is 
expressed primarily in adipocytes—to 
impact insulin sensitivity in liver and 
muscle raises the possibility that fac-
tors secreted by adipocytes into the 
circulation (adipokines) may mediate 
this crosstalk.
One of the paradoxes raised by 
the finding that fatty acids activate 
Toll-like receptors and inflammatory 
signaling pathways is the implica-
tion that nutrient abundance, such 
as occurs during feeding, may be a 
trigger for inflammation in adipose 
tissue. The authors propose that 
STAMP2 may be a counter-regula-
tory factor that prevents inappro-
priate activation of inflammatory 
pathways during fluctuations in 
nutrient exposure or under nutri-
ent-rich conditions such as feed-
ing. STAMP2 may therefore serve 
to integrate inflammatory pathways 452 Cell 129, May 4, 2007 ©2007 Elsevieand metabolic homeostasis (Figure 
1). Although this idea is supported 
by the observation that loss of 
STAMP2 expression compromises 
adipocyte function, it will be impor-
tant to determine whether elevation 
of STAMP2 expression actively pro-
tects adipocytes against inflamma-
tory challenge.
As with any new player in inflam-
mation and metabolism, a number 
of questions remain to be answered. 
Among the most important unre-
solved issues is the cellular mecha-
nism through which STAMP2 exerts its 
inflammatory and metabolic effects. 
The fact that it is a transmembrane 
protein immediately suggests several 
possibilities. Interestingly, STAMP2 
belongs to the STAMP or STEAP fam-
ily of six transmembrane domain pro-
teins (Ohgami et al., 2005). Members 
of this family are metalloreductases, 
which are important for the cellular 
import of iron and copper. Is this activ-
ity of STAMP2 required for its suppres-
sive effect on inflammatory responses 
and for its role in maintaining proper 
insulin signaling in adipocytes? Does 
the inability to properly handle iron or 
copper in adipocytes lead to inflam-
mation? If so, future studies may shed 
new light on the role of metal metabo-
lism in immune responses and glu-
cose metabolism.r Inc.Another provocative feature of 
STAMP2 is its dynamic expression: 
STAMP2 is induced by nutrients/
feeding and by cytokines such as 
TNFα. What are the molecular path-
ways that regulate STAMP2 expres-
sion and how are these pathways 
disrupted in obese/diabetic animals? 
Does loss of STAMP2 regulation in 
obese/diabetic mice play a causal 
role in the development of insulin 
resistance and increased inflamma-
tory tone in adipose tissue of these 
animals? Future studies should 
determine whether forced expres-
sion of STAMP2 in adipose tissue of 
obese/diabetic mice rescues aspects 
of the defective metabolic or inflam-
matory phenotype. Finally, although 
the new work focuses primarily on 
the metabolic impact of STAMP2, 
it will be interesting to address the 
potential role of STAMP2 in immunity 
and inflammation.
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